Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference https://lnkd.in/eiGXaphV #anavex #biopharma #neuroscience #precisionmedicine
Anavex Life Sciences
Biotechnology Research
New York City, NY 4,783 followers
Anavex utilizes genomic biomarkers in precision medicine to treat severe neurological disorders
About us
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com.
- Website
-
http://www.anavex.com
External link for Anavex Life Sciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York City, NY
- Type
- Public Company
Locations
-
Primary
Get directions
New York City, NY 10019, US
Employees at Anavex Life Sciences
Updates
-
Anavex Life Sciences Announces Expansion of Leadership Team https://lnkd.in/e5nkpcX2 #anavex #biopharma #neuroscience #precisionmedicine
-
-
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ #anavex #biopharma #neuroscience #precisionmedicine https://lnkd.in/ev4hdCKd
-
-
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time https://lnkd.in/eAXUNqnM #anavex #biopharma #neuroscience #precisionmedicine
-
-
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET https://lnkd.in/dSiBfFtW #anavex #biopharma #neuroscience #precisionmedicine
-
-
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference https://lnkd.in/eQE3CRz7 #Anavex #Biopharma #neuroscience #precisionmedicine
-
-
From Autism to Alzheimer's: A recent study identifies brain energy metabolism dysfunction as a common driver of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, intellectual disability, autism spectrum disorders, schizophrenia, bipolar disorder, and depressive disorders. SIGMAR1, which is activated by ANAVEX compounds, has been demonstrated to normalize brain energy metabolism at the mitochondrial level, upstream of pathways common to neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. #anavex #Biopharma #neuroscience #precisionmedicine
-
-
The accumulation of 'junk proteins' has been identified as one cause of aging. SIGMAR1, which is activated by ANAVEX compounds, has been demonstrated to reduce accumulation of junk proteins. #anavex #Biopharma #neuroscience #precisionmedicine
-
-
Anavex Life Sciences reposted this
The newly issued FDA's draft guidance for developing drugs against Alzheimer's, a first update since 2018, paves the way for the extensive use of Artificial Intelligence and modern biological tools that are linked to our molecular understanding of the disease progression. Promoting the use of patient selection biomarkers the agency notes that "It is expected that biomarker evidence of disease will establish the reliable diagnosis of subjects in trials". Furthermore, it establishes that "Surrogate endpoints or intermediate clinical endpoints that do not directly measure clinical benefit but that are considered reasonably likely to predict clinical benefit may support an accelerated approval". Within this framework, the power of eXplainable Artificial Intelligence tools combined with the broad availability of multi-omic data for a large number of patients will likely fuel the discovery and validation of truly novel biomarkers, providing the quantum leap needed to combat this disease. This novel framework that guides the discussions between drug makers and the FDA is likely to further accelerate the pace of innovation for Alzheimer's patients, building on very recent successes. Jacques Touchon Federico Goodsaid Hichem Chakroun Thomas TURCAT Frédéric Parmentier Véronique Chabernaud #FDA #ALZHEIMER'S #PRECISIONMEDICINE #AI #BIOMARKERS #GENOMICS
-
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference #anavex #biopharma #neuroscience #precisionmedicine https://lnkd.in/e7ZYSQCA
-